Obseva Logo highresolution.jpg
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
February 28, 2024 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Obseva Logo highresolution.jpg
Geneva Court Grants Temporary Moratorium to ObsEva
January 31, 2024 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Obseva Logo highresolution.jpg
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
November 30, 2023 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Obseva Logo highresolution.jpg
Organon Returns Ebopiprant to XOMA
October 27, 2023 17:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Obseva Logo highresolution.jpg
ObsEva Files half Year 2023 Financial Statements
September 27, 2023 01:00 ET | ObsEva SA
ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a...
Obseva Logo highresolution.jpg
ObsEva Recovers Full Worldwide Rights on Nolasiban
July 13, 2023 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – July 13, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Obseva Logo highresolution.jpg
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023
June 30, 2023 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Obseva Logo highresolution.jpg
Annual General Meeting 2023
June 08, 2023 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 8, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Obseva Logo highresolution.jpg
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
May 02, 2023 01:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...
Obseva Logo highresolution.jpg
ObsEva Annual Report 2022
April 28, 2023 12:00 ET | ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...